key: cord-0919148-5asyadk4
authors: Tyner, Harmony L; Burgess, Jefferey L; Grant, Lauren; Gaglani, Manjusha; Kuntz, Jennifer L; Naleway, Allison L; Thornburg, Natalie J; Caban-Martinez, Alberto J; Yoon, Sarang K; Herring, Meghan K; Beitel, Shawn C; Blanton, Lenee; Nikolich-Zugich, Janko; Thiese, Matthew S; Pleasants, Jessica Flores; Fowlkes, Ashley L; Lutrick, Karen; Dunnigan, Kayan; Yoo, Young M; Rose, Spencer; Groom, Holly; Meece, Jennifer; Wesley, Meredith G; Schaefer-Solle, Natasha; Louzado-Feliciano, Paola; Edwards, Laura J; Olsho, Lauren E W; Thompson, Mark G
title: Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
date: 2021-12-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1038
sha: 1ee35d197ae579b211cef30ed497b53594baa47a
doc_id: 919148
cord_uid: 5asyadk4

BACKGROUND: Data on the development of neutralizing antibodies against SARS-CoV-2 after SARS-CoV-2 infection and after vaccination with messenger RNA (mRNA) COVID-19 vaccines are limited. METHODS: From a prospective cohort of 3,975 adult essential and frontline workers tested weekly from August 2020 to March 2021 for SARS-CoV-2 infection by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) assay irrespective of symptoms, 497 participants had sera drawn after infection (170), vaccination (327), and after both infection and vaccination (50 from the infection population). Serum was collected after infection and each vaccine dose. Serum-neutralizing antibody titers against USA-WA1/2020-spike pseudotype virus were determined by the 50% inhibitory dilution. Geometric mean titers (GMTs) and corresponding fold increases were calculated using t-tests and linear mixed effects models. RESULTS: Among 170 unvaccinated participants with SARS-CoV-2 infection, 158 (93%) developed neutralizing antibodies (nAb) with a GMT of 1,003 (95% CI=766-1,315). Among 139 previously uninfected participants, 138 (99%) developed nAb after mRNA vaccine dose-2 with a GMT of 3,257 (95% CI = 2,596-4,052). GMT was higher among those receiving mRNA-1273 vaccine (GMT =4,698, 95%CI= 3,186-6,926) compared to BNT162b2 vaccine (GMT=2,309, 95%CI=1,825-2,919). Among 32 participants with prior SARS-CoV-2 infection, GMT was 21,655 (95%CI=14,766-31,756) after mRNA vaccine dose-1, without further increase after dose-2. CONCLUSIONS: A single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed nAb response. Two doses of mRNA vaccine in previously uninfected participants resulted in higher nAb to SARS-CoV-2 than after one dose of vaccine or SARS-CoV-2 infection alone. Neutralizing antibody response also differed by mRNA vaccine product.

A humoral immune response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection or vaccination against COVID-19 is manifested in the development of neutralizing antibodies (nAb) against SARS-CoV-2, the causative agent for coronavirus disease 2019 and is thought to be predictive of protection against subsequent symptomatic and severe illness [1, 2] . Most studies of nAb response following SARS-CoV-2 infection have been conducted among patients with medically-attended and severe symptomatic COVID-19 [3, 4] . Less is known about nAb response following mildly symptomatic or asymptomatic infection or following vaccination administered in real-world conditions.

In a multi-center prospective cohort of essential and frontline workers, sera were collected before and after SARS-CoV-2 infection and before and after vaccination with messenger RNA (mRNA) COVID-19 vaccines. This study has four objectives: first, to describe nAb response following SARS-CoV-2 infection and examine whether nAb responses differed by illness characteristics, sociodemographic and health characteristics, viral shedding duration, or peak RNA load; second, to describe nAb responses in previously uninfected participants 2-3 weeks following one or two doses of mRNA vaccines and examine whether nAb response differed by socio-demographic or health characteristics, febrile symptoms, or the use of analgesics before or after vaccination [5] . Response to mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) mRNA vaccines was also compared. A third objective was to describe nAb response following mRNA vaccination among participants who were infected with SARS-CoV-2 prior to vaccination, and fourth, to Portland, Oregon; Temple, Texas; and Salt Lake City, Utah) that share a common protocol and methods [6] [7] [8] . The cohort of 3,975 participants from which the three analytic samples are drawn has been described in a previous publication [7] . At the time of enrollment, all participants provided written consent. This study was approved by an Institutional Review Board (IRB) at each participating institution. §

August 2020 to March 2021 Participants completed electronic surveys at the time of enrollment that collected sociodemographic and health characteristics. Participants self-collected a mid-turbinate nasal swab weekly and collected an additional mid-turbinate swab and saliva specimen at the onset of COVID-19-like illness (CLI), defined as one or more symptom(s) of fever, chills, cough, shortness of breath, sore throat, diarrhea, muscle aches, and/or a change in smell or taste.

When CLI was identified, participants completed electronic surveys at the beginning and end of symptoms to describe duration of illness and the presence or absence of fever, feverishness, chills, or a measured temperature higher than 38℃ (100 ℉).

Participants provided a serum specimen upon enrollment and every 3 months thereafter, about 30 days after a first SARS-CoV-2 positive swab (convalescent), and 14-21 days after each vaccine dose received.

A c c e p t e d M a n u s c r i p t Vaccination Status and Participant-Reported Events Following Vaccination COVID-19 vaccination status was collected through (1) participant self-report by electronic and telephone surveys, (2) upload of vaccine card images after each dose, (3) review of vaccination records in electronic medical or occupational health records, and (4) review of state immunization information systems in Minnesota, Oregon, Texas, and Utah.

Participants reported fever and use of analgesics before and after each vaccine dose through electronic surveys [7] .

Self-collected mid-turbinate swab specimens were shipped on cold packs and tested for SARS-CoV-2 by qualitative reverse-transcription polymerase chain reaction (RT-PCR) assay at Marshfield Clinic Laboratory (Marshfield, WI). Quantitative RT-PCR was done at the Wisconsin State Laboratory of Hygiene (Madison, Wisconsin). Both tests used methods described in a previous publication [7] .

Serum-neutralizing antibodies were measured against wild or United States' origin USA-WA1/2020-spike pseudotype virus, similar to other evaluations prior to the widespread circulation of SARS-CoV-2 variants of concern [5, 8] . The USA-WA1/2020-spike pseudotype virus is an artificially created virus displaying the spike protein sequenced from a clinical SARS-CoV-2 isolate, providing a standardized viral proxy to measure antibody response. The resulting serum-neutralizing antibodies were calculated as the 50% inhibitory dilution (ID50). These serologic assays, which quantify the amount of host serum needed to neutralize pseudovirus infectivity, an in-vitro proxy for antibody-mediated protection against SARS-CoV-2, were conducted by LabCorp (South San Francisco, CA) staff blinded to SARS-CoV-2 infection status and vaccine product (Supplementary Appendix: Methods) [9] .

A c c e p t e d M a n u s c r i p t

Neutralizing antibodies were analyzed as log10 titers and back transformed to estimate geometric mean titers (GMTs). A titer of <40 (negative) was imputed as 20 (half the detectable limit) for analysis. For nAb following infection, 95% confidence intervals (CI) of GMT were calculated using one-sample t-tests. For nAb following vaccination, GMT and 95% CI were calculated using a linear mixed effects model, with a repeated measure for nAb following vaccine dose-1 and dose-2. Estimates were considered statistically different if their 95% CI did not overlap. In secondary analyses, we evaluated associations between sociodemographic or health characteristics and nAb measures using Pearson's chi-squared, Fisher's exact test, or one-way analysis of variance; p-values <.05 were considered statistically significant and interpreted as exploratory. The inclusion of days from infection or vaccination to sera collection and sociodemographic and health characteristics in the adjusted GMT models did not change point estimates by >5% and, thus, were not included in the adjusted models (Supplementary Appendix: Methods). Sociodemographic and health characteristics were similar across groups at enrollment (Table 1) . At least half were female (range across samples = 50%-58%), most were aged 18-49 years (64%-71%), and the majority self-reported their race as White (91%-92%).

Occupation was similar across groups; 12-28% were primary healthcare providers, 39-58% were nurses or other allied healthcare providers, 19-39% were first responders, and 1-9% were essential and other frontline workers. Most (67%-72%) participants were overweight (BMI 25-29.9 kg/m 2 ) or obese (BMI 30+ kg/m 2 ). Approximately one-half of participants described themselves as being in excellent or very good health (55%-71%), 22%-30% reported at least one chronic condition and at least one daily medication, and 15%-22% reported currently smoking tobacco products.

Of the 170 participants with RT-PCR-confirmed SARS-CoV-2 infection, most (92%) met symptom criteria for COVID-19; 8% were asymptomatic (Table 1) . Most infections had positive weekly swabs for 2 or more weeks (78%) and fever (60%); 28% required medical care, 6% sought emergency care, and 1% required hospitalization. The median time from first positive swab collection to convalescent sera collection for infected participants was 30 days (IQR=26-37). Neutralizing antibodies were detected among 158 (93%) infected participants ( Table 2, Table S1 ). GMT post-infection, including those without detectable antibodies, was 1,003 (95%CI=766-1,315) ( Table 2, Table S2 ). Neutralizing antibody GMT did not differ by SARS-CoV-2 infection characteristics, such as the presence or absence of febrile symptoms, duration of detectable virus ( Table 2, Table S2 ), or highest viral RNA load isolated from nasal swabs collected during infection (p=0.78) ( Figure S2 ). Participants who did not develop A c c e p t e d M a n u s c r i p t nAb after SARS-CoV-2 infection were more likely to be smokers (5 of 12 vs 21 of 158), (p=0.002) (Table S1 ).

Response to mRNA vaccination among previously uninfected participants Sera were collected a median of 18 days (IQR=15-20 days) after mRNA vaccine dose-1 of either vaccine product ( Table 2) . Neutralizing antibodies were detected among 108 of 139 participants (78%) after dose-1 with a nAb GMT of 250 (95%CI=199-312) ( Table 2) .

Neutralizing antibody GMT post-dose-1 was higher among those aged 18-49 years than those age 50 and older (p=0.05) and among those without chronic conditions (p=0.03) (Table S2) .

Sera were collected a median of 19 days (IQR=15-23) after mRNA vaccine dose-2 of either vaccine product ( Table 2 ). Neutralizing antibodies were detected among 138 of 139 participants (99%) with a nAb GMT of 3,237 (95%CI=2,596-4,052), a 13-fold (95%CI=10-16.8) increase in nAb titers (Table 2, Figure 2 , Figure S1 ). Participants with a normal BMI (18.5-24.9 kg/m 2 ) had lower nAb titers following dose-2 (p = 0.02) than those who were underweight, overweight, or obese (Table S2) . Those with febrile symptoms following dose-2 had higher nAb GMT versus those who did not (3,587 versus 2,236, p=0.004), as did those who reported taking analgesics after dose 2 (3,312 versus 2,351, p = 0.03) (Table S2) .

Among the previously uninfected, response to the mRNA vaccines differed by product. Thirty-eight participants received mRNA-1273 vaccine and 101 participants received BNT162b2 vaccine ( Table 2, Table S4 ). When comparing mRNA-1273 versus BNT162b2 recipients, mRNA-1273 recipients were more likely to be male (66% versus 44%) or a first responder (61% versus 4%) and less likely to be a primary health care provider (5% versus 37%) (Table S4 ). Among 38 recipients of the mRNA-1273 vaccine, nAb GMT after dose 1 was 404 (95% CI=275-594) and increased 11-fold to 4,698 GMT (95%CI=3,186-6,926) following dose-2 (Table 2, Figure 3A ). Among 101 recipients of the BNT162b2 A c c e p t e d M a n u s c r i p t vaccine, nAb GMT after dose-1 was 156 (95%CI=123-197) and increased 15-fold to 2,309 GMT (95% CI=1,825-2,919) following dose-2. Neutralizing antibody GMT was statistically higher for recipients of mRNA-1273 vaccine compared to recipients of BNT162b2 vaccine after dose-1 and after dose-2 (p <0.001) (Table 2, Figure 3A ).

Among the 50 participants who were infected with SARS-CoV-2, then subsequently vaccinated with either mRNA vaccine who had sera collected after dose-1 alone, dose-2 alone, or both doses ( Figure S3 ), nAb GMT after infection and before vaccination was 1,438 (95% CI=1,012-2,042) ( Table 2 ). Among the 42 participants with sera collected following mRNA vaccine dose-1, nAb increased 15.1-fold to nAb GMT of 21,655 (95% CI=14,766-31,756). Among the 40 participants with sera collected following mRNA vaccine dose-2, the nAb GMT was 15,863 (95% CI=11,293-23,484) which was statistically unchanged from the nAb GMT after vaccine dose-1. Participants with a prior positive SARS-CoV-2 test result with at least one chronic condition had significantly higher nAb response following vaccine dose-1 (p=0.02) and dose-2 (p=0.02) ( Table S2 ). The pattern of nAb GMT increase was similar when analysis was restricted to the 32 participants with sera available for all 3 time points (Table S3) . Neutralizing antibody GMT estimates following vaccine dose-1 were higher for recipients of the mRNA-1273 vaccine compared to the BNT162b2 vaccine, but confidence intervals were broad and overlapping (Table 2; Figure 3B ). 

In a prospective cohort of essential and frontline workers with no prior history of SARS-CoV-2 infection, the nAb activity to pseudotype SARS-CoV-2 measured 2-3 weeks following a second dose of mRNA COVID-19 vaccine was 13-fold higher than nAb activity measured following a single mRNA vaccine dose and over 3-fold higher than nAb activity measured 4-5 weeks after SARS-CoV-2 infection. Almost all study participants (99%) who received two doses of mRNA vaccine developed nAb, while no nAb were detected among 22% of participants following a single dose of an mRNA vaccine and 7% of adults following SARS-CoV-2 infection. The superior immunogenicity of two doses of mRNA vaccine compared to a single dose in real-world conditions is consistent with findings from efficacy trials [10, 11] and other recent observational studies [7] . However, our study is among the first to compare humoral immunogenicity to vaccination with humoral immune response to SARS-CoV-2 infection within the same cohort using common laboratory methods [12] [13] [14] .

Vaccination had the greatest impact among adults with a prior positive SARS-CoV-2 test result; in this group of participants, nAb GMT was 21,655 following one dose of mRNA vaccine compared to a nAb GMT of 3,237 following two mRNA vaccine doses among previously uninfected adults, a difference of over 6-fold. This is comparable to the over-6fold difference observed by Krammer et al [15] and other studies, and consistent with other A c c e p t e d M a n u s c r i p t findings that mRNA vaccine boosts humoral immune response to previous infection [15] [16] [17] [18] .

Like other studies, we found that a second dose did not further boost immune response among those with a previous infection [15] [16] [17] [18] . Our results support the sufficiency of a single dose of mRNA vaccine to boost antibody response in most people with prior laboratoryconfirmed infection. Moreover, the measurable increase in nAb GMT after at least one dose of vaccination after prior infection compared to the nAb GMT rise after infection alone supports the benefit of vaccination in participants with a prior positive SARS-CoV-2 test result.

We found statistically significant differences in immunogenicity between mRNA vaccine products among participants with no prior infection. Neutralizing antibody GMT following a second dose of mRNA-1273 vaccine was 4,698compared to a nAb GMT of 2,309 following a second dose of BNT162b2 vaccine. Our study is among the first to compare the immunogenicity of the two mRNA vaccine products within the same cohort using the same laboratory methods, and our findings agree with other similar studies [19] , including described differences between convalescent titers and vaccination by product [2, [20] [21] [22] [23] .

Although a 2-fold difference between mRNA vaccine products in post-vaccination titers merits further investigation, note that within this same cohort, vaccination with either mRNA vaccine product was associated with similar and high vaccine effectiveness against SARS-CoV-2 infection [24, 25] . Although we have not observed differences in vaccine effectiveness (VE) against mild COVID-19 between mRNA products within this cohort [26] , studies of more severe COVID-19-associated hospitalization have reported higher VE for mRNA-1273 compared to BNT1262b2 [27] , consistent with the pattern of nAb differences reported here. The GMT value necessary to provide protection has not been well described although titer correlates for protection have been proposed [2, 28, 29] .

A c c e p t e d M a n u s c r i p t Unlike other studies which have observed a correlation between more severe SARS-CoV-2 infection and higher antibody response [30] [31] [32] [33] [34] [35] [36] [37] , an association was not observed between febrile symptoms during infection, weeks of virus detection, or nasal viral RNA load and the development of nAb. Most prior studies focused on cases of severe COVID-19, often requiring hospitalization, while most of the infections examined in this study were mild and did not require hospitalization. Another reassuring finding was the lack of association between analgesic use before or after vaccination and reduced immunogenicity, which has been reported for some other vaccines [5] . In this study, analgesic use following a second mRNA vaccine dose was associated with higher nAb response. This may be related to our other finding that self-reported febrile symptoms following the second mRNA vaccine dose were also associated with higher antibody response. Similar associations between postvaccination fever and immunogenicity have been noted for influenza vaccines [38] .

Strengths of this multi-site study include routine weekly and illness testing irrespective of symptoms for SARS-CoV-2 infection by a molecular assay, collection of illness symptoms, documentation of viral load and duration of viral shedding, multimethod documentation of vaccination status, collection and processing of sera using common procedures, and the measurement of nAb to SARS-CoV-2 using a validated assay at a wellestablished and accredited clinical reference laboratory.

This study also has at least six limitations. First, nAb responses could only be examined within the time intervals of vaccination that occurred in our study. Inferences regarding antibody response following mRNA vaccine dose-1 are limited to the 2 to 3 weeks between vaccine doses, because most individuals had their second vaccine dose at the shortest recommended time interval. Second, serum-neutralizing antibodies were measured against USA-WA1/2020-spike pseudotype virus rather than with a live virus assay. However, previous studies have shown concordance between nonreplicating pseudotype neutralization A c c e p t e d M a n u s c r i p t and SARS-CoV-2 neutralization assays [39, 40] . Third, the nAb assays against USA-WA1/2020-spike pseudotype virus were performed by LabCorp using the PhenoSense® assay. The assay was validated before WHO standards were widely available, and the results are not reported in international units, therefore they are not directly translatable to assays performed by other laboratories. Fourth, cellular mediated immunogenicity could not be examined, which additionally contributes to clinical protection. In the same cohort, high vaccine effectiveness was noted in preventing SARS-CoV-2 infection starting 14 days after mRNA vaccine dose 1 [7] . Fifth, because of sparse data and limited sociodemographic and health heterogeneity, we were unable to fully examine or adjust for factors that may be M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t Abbreviations: Neutralizing antibodies (nAb); Not applicable (NA); Messenger RNA (mRNA); Adjusted Geometric Mean Titer (aGMT); Geometric Mean Ratio (GMR) † Geometric mean ratio is fold-change in nAb from dose-1 to dose-2 adjusting for days from dose-1 vaccination to post-dose-1 sera collection and for days from dose-2 to post-dose-2 sera-collection. Unadjusted fold-change from infection to dose-1 was 12.7 for BNT162b2 (Pfizer-BioNTech) and 40.1 for mRNA-1273 (Moderna). ‡ Post-infection GMT for all participants is the crude estimate without adjustment.

¥ Median (IQR) days from dose-1 to dose-2 for BNT162b2 (Pfizer-BioNTech) was 21 (21) (22) and for mRNA-1273 (Moderna) was 29 (27) (28) (29) (30) (31) A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 3 

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

Effect of antipyretic analgesics on immune responses to vaccination

COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) Study: Protocol for a multi-site longitudinal cohort

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without postacute symptoms

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Comparative Effectiveness of Moderna

Hospitalizations Among Adults Without Immunocompromising Conditions -United States

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

Evolution of immune responses to SARS-CoV-2 in mildmoderate COVID-19

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

A c c e p t e d M a n u s c r i p t